Tigress Financial analyst Ivan Feinseth raised the firm’s price target on Medline (MDLN) to $60 from $55 and keeps a Buy rating on the shares. Multiple durable growth levers support “superior” market growth and margin expansion, contends the analyst, who notes that the firm’s 12-month target price represents a potential return of 36% from current levels.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline 75M share Secondary priced at $41.00
- Medline announces launch of secondary offering of Class A common stock
- Medline files to sell 75M shares of Class A common stock for holders
- Medline price target raised to $56 from $52 at Truist
- Conservative 2026 Guidance and Strong Segment Fundamentals Underpin Buy Rating and $53 Target for Medline